Researchers develop novelties in the treatment of lung cancer, and are making a clinical breakthrough by increasing the number of patients who achieve complete tumor reduction to 36.8%.
The new treatment strategy consists of administering preoperative chemotherapy to patients in the early stages. Photo: shutterstock.
Knowing that at the time of diagnosis more than a third Lung cancer patients You have early-stage disease or locally advanced disease. a
The group of investigators belonging to the Hispanic Group of Lung Cancer (GECP) influences the percentage of patients who achieve long-term complete remission of their tumor. Scientific progress, considering that only 30% of patients with this type of cancer in the early stages survive more than 5 years.
Neither surgery nor radiotherapy alone is associated with good outcomes, “in these cases there are usually minute node metastases, so most patients eventually relapse, with two-thirds of systemic relapses,” Mariano says. Provencio, chief of GECP, chief of oncology at Puerta de Hierro Hospital, and principal investigator of this study.
A new treatment strategy, involving pathologists, surgeons, oncologists, or radiotherapists, is to administer preoperative chemoimmunotherapy to patients in the early stages. “We’re not talking about just one drug. We’re talking about a change in approach and treatment strategy. We’ve found a significant improvement that could lead us to treat a large number of these patients after decades without progress,” explains Provencio.
This treatment approach also achieves greater Overall objective response rate75.4 percent of patients responded to chemotherapy, compared to 48.2 percent in the control group. In addition, it would allow for an increase in the number of patients who could finally become operable: 93 percent of patients in the combination therapy group underwent surgery after treatment, compared to 69 percent in the control group.
“It is possible that more people will have surgery in this way because this treatment is more effective in reducing the size of the tumor, without adding a lot of toxicity,” Provencio explains.
one of the points Strengths of studying Spanish is that it focuses on patients with locally advanced stage IIIA, who are in dire need of clinical improvement. For the President of GECP, “GECP data contribute significantly to the establishment One Standard of Care for Surgical stage disease Third, it brings great benefits.
Specifically, these good results have stimulated Quick approval from From the US Food and Drug Administration (FDA) so that this Treatment schedule is available in North American hospitals. “We hope that Europe, and therefore Spain, will follow this path because without it,” he added Doubt is an obvious benefit For patients with a severe tumor.
Data from the NADIM II study, which in Spain recruited 86 patients from twenty hospital centers, will be presented on June 5, at the American Society of Oncology (ASCO) conference.
Source consult here.